MedPage Today on MSN

First drug for deadly transplant complication gets FDA's blessing

The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...

FDA Approves Omeros' First-In-Class Drug For Rare Transplant Complication

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
Fierce Pharma

Omeros scores its first-ever FDA nod for stem cell transplant drug Yartemlea

Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the ...
The Caledonian-Record

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

YARTEMLEA is approved by the U.S. FDA for the treatment of TA-TMA in adults and in children ages two years and older. A marketing authorization application for YARTEMLEA for TA-TMA is under review by ...
The Pharma Letter

Omeros rockets as FDA approves Yartemlea

Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that ...
Business Wire

Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA

MASP-2 is the effector enzyme of the lectin pathway, one of the principal complement activation pathways. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent ...
TipRanks on MSN

Omeros announces FDA-approved YARTEMLE for treatment of TA-TMA

Omeros (OMER) announced that the U.S. Food and Drug Administration, FDA, has approved YARTEMLE for the treatment of hematopoietic stem cell ...
Yahoo Finance

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

SEATTLE, September 02, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival ...
Seeking Alpha

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing ...
Business Wire

Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the European Medicines Agency (EMA) has appointed rapporteurs for the company’s marketing authorization application ...
Healio

Sickle cell disease increases risk for transplant-associated thrombotic microangiopathy

Please provide your email address to receive an email when new articles are posted on . SALT LAKE CITY — Sickle cell disease increased risk for transplant-associated thrombotic microangiopathy among ...
AOL

Two-Year Data Show Long-Term Benefits of Chronic Soliris® Therapy in Patients with aHUS

aHUS is an ultra-rare, life-threatening, chronic genetic disease that can progressively damage vital organs, leading to stroke, heart attack, kidney failure, and death. 4 The morbidity and premature ...